Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 1/2021

01-01-2021 | Post-Exposure Prophylaxis | Original Paper

Factors Associated with Preferred Pre-Exposure Prophylaxis Dosing Regimen Among Men Who Have Sex with Men in Real-World Settings: A Mixed-Effect Model Analysis

Authors: Huei-Jiuan Wu, Stephane Wen-Wei Ku, Chia-Wen Li, Nai-Ying Ko, Tsung Yu, An-Chun Chung, Carol Strong

Published in: AIDS and Behavior | Issue 1/2021

Login to get access

Abstract

When provided with both choices of pre-exposure prophylaxis (PrEP) in MSM, men may choose to use either method based on their sexual practice. The study objective was to describe the switches between dosing regimens and identify factors that predict choice of a dosing regimen among MSM. We performed a multi-center, observational, prospective PrEP cohort study conducted at three study sites in Taiwan between January 2018 and March 2019. A total of 215 participants made 469 visits. In half of the visits (49.7%), participants reported using on-demand PrEP. There were 36 regimen switches: 20 from daily to on-demand and 16 from on-demand to daily. Among 28 participants who switched regimens, 22 switched regimens once and 6 switched more than once. The frequency of condomless anal sex and a history of post-exposure prophylaxis use were associated with taking PrEP on-demand (p < 0.05). PrEP adherence intervention should be tailored specifically to sexual behavior to increase adherence to PrEP.
Literature
1.
Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New Engl J Med. 2010;363(27):2587–99.CrossRef
2.
Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. New Engl J Med. 2012;367(5):399–410.CrossRef
3.
Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. New Engl J Med. 2012;367(5):423–34.CrossRef
4.
Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (London, England). 2013;381(9883):2083–90.CrossRef
5.
Molina JM, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. New Engl J Med. 2015;373(23):2237–46.CrossRef
6.
McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet (London, England). 2016;387(10013):53–60.CrossRef
7.
World Health Organization. Technical brief: what’s the 2+ 1+ 1? Event-driven oral pre-exposure prophylaxis to prevent HIV for men who have sex with men: update to WHO’s recommendation on oral PrEP. Geneva: World Health Organization; 2019.
8.
Nichols BE, Boucher CA, van der Valk M, Rijnders BJ, van de Vijver DA. Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study. Lancet Infect Dis. 2016;16(12):1423–9.CrossRef
9.
Tan DHS, Hull MW, Yoong D, et al. Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis. CMAJ. 2017;189(47):E1448–E14581458.CrossRef
10.
British HIV Association. BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP) 2018. London: British HIV Association; 2018.
11.
Chu IYH, Ku SWW, Li CW, et al. Taiwan guideline on oral pre-exposure prophylaxis for HIV prevention-2018 update. J Microbiol Immunol Infect. 2020;53(1):1–10.CrossRef
12.
European AIDS Clinincal Society (EACS). European Guidelines for treatment of HIV-positive adults in Europe Guidelines. Brussels: European AIDS Clinincal Society (EACS); 2018.
13.
Wright E, Grulich A, Roy K, et al. Australasian Society for HIV, viral hepatitis and sexual health medicine HIV pre-exposure prophylaxis: clinical guidelines. J Virus Erad. 2017;3:168–84.CrossRef
14.
Mannheimer S, Hirsch-Moverman Y, Franks J, et al. Factors associated with sex-related pre-exposure prophylaxis adherence among men who have sex with men in New York City in HPTN 067. JAIDS. 2019;80(5):551.PubMed
15.
Cornelisse VJ, Lal L, Price B, et al. Interest in Switching to on-demand HIV pre-exposure prophylaxis (PrEP) among Australian users of daily PrEP: an online survey. Open forum Infect Dis. 2019;6(7):ofz287.CrossRef
16.
Molina JM, Charreau I, Spire B, et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017;4(9):e402–e410410.CrossRef
17.
Noret M, Balavoine S, Noret M, et al. Daily or on demand oral TDF/FTC for HIV pre-exposure prophylaxis: experience from an hospital-based clinic in France. AIDS (London, England). 2018;32(15):2161–9.CrossRef
18.
Hoornenborg E, Achterbergh RC, van der Loeff MFS, et al. Men who have sex with men more often chose daily than event-driven use of pre-exposure prophylaxis: baseline analysis of a demonstration study in Amsterdam. J Int AIDS Soc. 2018;21(3):e25105.CrossRef
19.
Taiwan Centers for Disease control. Statistics of HIV/AIDS monthly report. Taipei: Taiwan Centers for Disease control; 2019.
20.
21.
22.
Wu H, Strong C, Ku S, et al. Syphilis acquisition and dosing schedule for pre-exposure prophylaxis (PrEP) users in Taiwan PrEP demonstration project. Poster presented at the 22nd International AIDS Conference Amsterdam, the Netherlands; 2018.
23.
Holloway I, Dougherty R, Gildner J, et al. PrEP uptake, adherence, and discontinuation among California YMSM using geosocial networking applications. JAIDS. 2017;74(1):15.PubMed
24.
Lee YC, Chang SY, Lin KY, et al. Awareness and willingness towards pre-exposure prophylaxis against HIV infection among individuals seeking voluntary counselling and testing for HIV in Taiwan: a cross-sectional questionnaire survey. BMJ Open. 2017;7(10):e015142.CrossRef
25.
National Institute for Health and Care Excellence. Pre-exposure prophylaxis of HIV in adults at high risk: Truvada (emtricitabine/tenofovir disoproxil). London: National Institute for Health and Care Excellence; 2019.
26.
27.
28.
Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–7.CrossRef
29.
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–13.CrossRef
30.
Vonesh EF, Carter RL. Mixed-effects nonlinear regression for unbalanced repeated measures. Biometrics. 1992;48:1–17.CrossRef
31.
Molina JM, Ghosn J, Béniguel L, et al. Incidence of HIV-infection in the ANRS Prevenir study in Paris region with daily or on-demand PrEP with TDF/FTC. AIDS 2018; Amsterdam, 2018.
32.
Zimmermann HM, Eekman SW, Achterbergh RC, et al. Motives for choosing, switching and stopping daily or event-driven pre-exposure prophylaxisa qualitative analysis. J Int AIDS Soc. 2019;22(10):e25389.CrossRef
33.
Reyniers T, Nostlinger C, Laga M, et al. Choosing between daily and event-driven pre-exposure prophylaxis: results of a belgian PrEP demonstration project. J Acquir Immune Defic Syndr. 2018;79(2):186–94.CrossRef
34.
Hoornenborg E, Coyer L, Achterbergh RC, et al. Sexual behaviour and incidence of HIV and sexually transmitted infections among men who have sex with men using daily and event-driven pre-exposure prophylaxis in AMPrEP: 2 year results from a demonstration study. Lancet HIV. 2019;6(7):e447–e45555.CrossRef
35.
Underhill K, Guthrie KM, Colleran C, et al. Temporal fluctuations in behavior, perceived HIV risk, and willingness to use pre-exposure prophylaxis (PrEP). Arch Sex Behav. 2018;47(7):2109–21.CrossRef
36.
Patel VV, Ginsburg Z, Golub SA, et al. Empowering with PrEP (E-PrEP), a peer-led social media–based intervention to facilitate HIV preexposure prophylaxis adoption among young black and latinx gay and bisexual men: protocol for a cluster randomized controlled trial. JMIR Res Protoc. 2018;7(8):e11375.CrossRef
37.
Dehlin JM, Stillwagon R, Pickett J, Keene L, Schneider JA. # PrEP4Love: an evaluation of a sex-positive HIV prevention campaign. JMIR Public Health Surveill. 2019;5(2):e12822.CrossRef
38.
Lachowsky NJ, Tattersall TL, Sereda P, et al. Community awareness of, use of and attitudes towards HIV pre-exposure prophylaxis (PrEP) among men who have sex with men in Vancouver, Canada: preparing health promotion for a publicly funded PrEP program. Sexual Health. 2019;16(2):180–6.PubMed
39.
40.
Vaccher SJ, Gianacas C, Templeton DJ, et al. Baseline preferences for daily, event-driven, or periodic HIV pre-exposure prophylaxis among gay and bisexual men in the PRELUDE demonstration project. Front Public Health. 2017;5:341.CrossRef
41.
Siguier M, Mera R, Pialoux G, et al. First year of pre-exposure prophylaxis implementation in France with daily or on-demand tenofovir disoproxil fumarate/emtricitabine. J Antimicrob Chemother. 2019;74(9):2752–8.CrossRef
42.
Closson EF, Mitty JA, Malone J, Mayer KH, Mimiaga MJ. Exploring strategies for PrEP adherence and dosing preferences in the context of sexualized recreational drug use among MSM: a qualitative study. AIDS Care. 2018;20(2):191–8.CrossRef
43.
Ku S, Strong C, Huang P, et al. Characteristics of men who have sex with men engaging "Chemsex" ands its prevalence in Taiwan: 2017 Hornet/Heart Survey. Poster presented at the 22nd International AIDS Conference Amsterdam, the Netherlands; 2018.
Metadata
Title
Factors Associated with Preferred Pre-Exposure Prophylaxis Dosing Regimen Among Men Who Have Sex with Men in Real-World Settings: A Mixed-Effect Model Analysis
Authors
Huei-Jiuan Wu
Stephane Wen-Wei Ku
Chia-Wen Li
Nai-Ying Ko
Tsung Yu
An-Chun Chung
Carol Strong
Publication date
01-01-2021
Publisher
Springer US
Published in
AIDS and Behavior / Issue 1/2021
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-020-02964-5

Other articles of this Issue 1/2021

AIDS and Behavior 1/2021 Go to the issue

Substantive Review

COVID-19 Among People Living with HIV: A Systematic Review

Correction

Correction to: Conceptualization of Empowerment and Pathways Through Which Cash Transfers Work to Empower Young Women to Reduce HIV Risk: A Qualitative Study in Tanzania

Original Paper

Sex in the Time of COVID-19: Results of an Online Survey of Gay, Bisexual and Other Men Who Have Sex with Men’s Experience of Sex and HIV Prevention During the US COVID-19 Epidemic

Original Paper

Sexual Health of Rural and Urban Young Male Couples in the United States: Differences in HIV Testing, Pre-exposure Prophylaxis Use, and Condom Use

Original Paper

Alcohol Use and Antiretroviral Adherence Among Patients Living with HIV: Is Change in Alcohol Use Associated with Change in Adherence?

Original Paper

Psychological Distress Among HIV Healthcare Providers During the COVID-19 Pandemic in China: Mediating Roles of Institutional Support and Resilience
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits